Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Zacks.com on MSN14h
FTC Report Reveals PBM Practices Impacting Competition and Drug CostsThe FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...
The U.S. Federal Trade Commission on Tuesday published the second part of its investigation into how prescription drug ...
BofA sees 2025 challenges for healthcare tech and distributors but upgrades Cardinal Health and Henry Schein, highlighting ...
From PBMs to abortion, there are plenty of health policy issues that will vie for the spotlight in 2025. For pharma marketers ...
Banning PBM spread pricing in Medicaid-managed care ... We sell different types of products and services to both investment professionals and individual investors. These products and services ...
The Conversation on MSN20d
What are pharmacy benefit managers? A health economist explains how lack of competition drives up drug prices for everyoneAs the middlemen between drug companies and insurers, PBMs are shoo-ins as the villains behind high drug prices. But they do ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback